Work

A Cost‐Effectiveness Analysis of FreeStyle Libre Real‐Time Continuous Glucose Monitoring System Compared With Self‐Monitoring of Blood Glucose in Adults With Type 2 Diabetes on Basal Insulin Plus SGLT2 Inhibitor and/or GLP ‐1 Agonists in the United Kingdom

Year: 2026
Type: article
Abstract: ABSTRACT Aims We previously showed that FreeStyle Libre (FSL) real‐time continuous glucose monitoring system (rtCGM) reduces glycated haemoglobin (HbA1c) at 16 and 32 weeks compared with capillary self‐monitoring of blood glucose (SMBG) in adults with Type 2 diabetes and above target glucose levels, managed with basal insulin and SGLT‐2 inhibitor and/or GLP‐1 agonist therapy. We assess the cost‐effectiveness of rtCGM compared with SMBG. Materials and Methods Participant‐level baseline and follow‐up health status (Euroqol‐5‐dimensions‐5‐levels) and within‐trial healthcare resource‐use data were collected. We estimated quality‐adjusted life‐years (QALYs) and participant‐level costs at 16 and 32 weeks. Long‐term cost‐effectiveness from the United Kingdom National Health Service perspective was evaluated using the IQVIA CORE Diabetes Model with a 3.5% discount rate. Sensitivity analyses assessed structural and parameter uncertainty. Results Within‐trial analyses found no significant difference at 32 weeks between rtCGM and SMBG in QALYs or healthcare costs. At 32 weeks, adjusted incremental QALYs were −0.015 (95% CI: −0.031 to 0.003) and incremental costs were £254 (95% CI: −£587 to £1070). The lifetime projected incremental QALYs were 0.730 (95% CI: 0.688–0.773) and incremental costs were £4341 (95% CI: 3558–5125), generating an incremental cost‐effectiveness ratio (ICER) of £5943 per QALY. At least 4 years of maintained glycaemic benefits are required for rtCGM to be cost‐effective. Sensitivity analyses were robust to the base‐case results. Conclusions Benefits of FSL rtCGM in lowering HbA1c in people with Type 2 diabetes on basal insulin plus SGLT‐2 inhibitor and/or GLP‐1 agonist therapy is likely to justify costs through improved health outcomes and reduced long‐term costs of diabetes‐related complications.
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $5,380
OpenAlex ID: W7233564884
FWCI:
Cites: 48
Cited by:
Related to: